<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Contributions of important cytokines, chemokines, colony-stimulating factors, and growth factors to immunologic responses</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Contributions of important cytokines, chemokines, colony-stimulating factors, and growth factors to immunologic responses</h1>
<div class="graphic"><div class="figure"><div class="ttl">Contributions of important cytokines, chemokines, colony-stimulating factors, and growth factors to immunologic responses</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="10%"></colgroup><colgroup span="4" width="20%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Immunomodulatory factor</td> <td class="subtitle1">Source</td> <td class="subtitle1">Critical functions</td> <td class="subtitle1">US FDA-approved uses for clinical disease</td> <td class="subtitle1">Targeted agents</td> <td class="subtitle1">Diseases treated</td> </tr> <tr class="divider_top"> <td class="subtitle2_left" colspan="6">Cytokines</td> </tr> <tr class="divider_bottom"> <td class="indent1">IL-1</td> <td> <p>Macrophages</p> Many cells</td> <td> <ul> <li>Fever, induces other cytokines, T cell stimulation</li> <li>Induces metalloproteinases and prostaglandins</li> <li>Increases adhesion molecule expression</li> </ul> </td> <td>None reported</td> <td>Anti-IL-1 beta: <ul class="decimal_heading"> <li>Canakinumab (SC)</li> <li>Rilonacept (SC)</li> </ul> IL-1 receptor antagonists: <ul class="decimal_heading"> <li>Anakinra (SC)</li> <li>OSP-101 (inhaled)</li> </ul> </td> <td>Cryopyrin-associated periodic syndromes (CAPS) <ul class="decimal_heading"> <li>Familial cold autoinflammatory syndrome (FCAS)</li> <li>Muckle-Wells syndrome (MWS)</li> <li>Neonatal-onset multisystem inflammatory disorder (NOMID)</li> </ul> <p>Deficiency of IL-1 receptor antagonist (DIRA)</p> <p>Tumor necrosis factor receptor 1-associated periodic syndrome (TRAPS)</p> <p>Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD)</p> <p>Familial Mediterranean fever (FMF)</p> <p>Systemic juvenile idiopathic arthritis (sJIA)</p> <p>Rheumatoid arthritis</p> Bronchiolitis obliterans</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="2">IL-2</td> <td class="divider_bottom" rowspan="2">T cells</td> <td class="divider_bottom" rowspan="2"> <ul> <li>Increase T cell proliferation, activates B cells</li> </ul> </td> <td class="divider_bottom" rowspan="2">Aldesleukin (IV): <ul class="decimal_heading"> <li>Malignant melanoma</li> <li>Renal cancer</li> </ul> </td> <td>Anti-IL-2 receptor alpha subunit: <ul class="decimal_heading"> <li>Basiliximab (IV)</li> </ul> </td> <td>Renal transplant (prophylaxis from graft rejection)</td> </tr> <tr class="divider_bottom"> <td>Anti-CD25 (high-affinity IL-2 receptor): <ul class="decimal_heading"> <li>Daclizumab (SC)</li> </ul> </td> <td>Multiple sclerosis</td> </tr> <tr class="divider_bottom"> <td class="indent1">IL-4</td> <td>T cells</td> <td> <ul> <li>Signal for immunoglobulin switch, increases IgE</li> <li>Decreases production of proinflammatory cytokines</li> <li>Suppresses delayed-type hypersensitivity (Th1 cells)</li> </ul> </td> <td>None reported</td> <td>Anti-IL-4R alpha (block IL-4 and IL-13 signaling): <ul class="decimal_heading"> <li>Dupilumab (SC)</li> </ul> </td> <td> <p>Eczema</p> Asthma</td> </tr> <tr class="divider_bottom"> <td class="indent1">IL-5</td> <td>T cells</td> <td> <ul> <li>Increases eosinophil production</li> </ul> </td> <td>None reported</td> <td> <p>Reslizumab (IV)</p> <p>Mepolizumab (SC)</p> Benralizumab (SC)</td> <td> <p>Eosinophilic asthma</p> Eosinophilic granulomatosis with polyangiitis</td> </tr> <tr class="divider_bottom"> <td class="indent1">IL-6</td> <td>Many cells</td> <td> <ul> <li>B and T cell proliferation, acute-phase reactants</li> <li>Induces natural protease inhibitor (TIMP)</li> </ul> </td> <td>None reported</td> <td> <p>Siltuximab (IV)</p> Anti-IL-6 receptor: <ul class="decimal_heading"> <li>Tocilizumab (IV/SC)</li> <li>Sarilumab (SC)</li> </ul> </td> <td> <p>Castleman disease</p> <p>Cytokine release syndrome</p> <p>Giant cell arteritis</p> <p>Polyarticular juvenile idiopathic arthritis (pJIA)</p> <p>Rheumatoid arthritis</p> Systemic juvenile idiopathic arthritis (sJIA)</td> </tr> <tr class="divider_bottom"> <td class="indent1">IL-12</td> <td>Macrophages</td> <td> <ul> <li>Increase IFN-gamma production and Th1 cell differentiation</li> </ul> </td> <td>None reported</td> <td>Anti-IL-12/IL-23: <ul class="decimal_heading"> <li>Ustekinumab (IV/SC)</li> </ul> </td> <td> <p>Crohn disease</p> <p>Plaque psoriasis</p> Psoriatic arthritis</td> </tr> <tr class="divider_bottom"> <td class="indent1">IL-13</td> <td>T cells</td> <td> <ul> <li>Similar to IL-4</li> </ul> </td> <td>None reported</td> <td>Anti-IL-4 receptor alpha (block IL-4 and IL-13 signaling): <ul class="decimal_heading"> <li>Dupilumab (SC)</li> </ul> </td> <td> <p>Eczema</p> Asthma</td> </tr> <tr class="divider_bottom"> <td class="indent1">IL-15</td> <td> <p>T cells</p> Macrophages</td> <td> <ul> <li>Induces TNF-alpha release from synovial macrophages, induces mitogenesis, and inhibits apoptosis</li> </ul> </td> <td>None reported</td> <td>None reported</td> <td>None reported</td> </tr> <tr class="divider_bottom"> <td class="indent1">IL-17</td> <td> <p>T cells</p> Innate lymphoid cells</td> <td> <ul> <li>Activates neutrophils and a variety of stromal cells to regulate host defense and also matrix disruption</li> </ul> </td> <td>None reported</td> <td> <p>Ixekizumab (SC)</p> <p>Secukinumab (SC)</p> Anti-IL-17 receptor alpha: <ul class="decimal_heading"> <li>Brodalumab (SC)</li> </ul> </td> <td> <p>Plaque psoriasis</p> <p>Psoriatic arthritis</p> Ankylosing spondylitis</td> </tr> <tr class="divider_bottom"> <td class="indent1">IL-23</td> <td> <p>Dendritic cells</p> Macrophages</td> <td> <ul> <li>Promotes T cell differentiation, particularly of the Th17 type</li> </ul> </td> <td>None reported</td> <td> <p>Tildrakizumab (SC)</p> <p>Guselkumab (SC)</p> Anti-IL-12/IL-23: <ul class="decimal_heading"> <li>Ustekinumab (IV/SC)</li> </ul> </td> <td> <p>Crohn disease</p> <p>Plaque psoriasis</p> Psoriatic arthritis</td> </tr> <tr class="divider_bottom"> <td class="indent1">TNF-alpha</td> <td> <p>T cells</p> Macrophages</td> <td> <ul> <li>Cachexia, induces other cytokines, T cell stimulation</li> <li>Induces metalloproteinases and prostaglandins</li> <li>Increases adhesion molecule expression</li> </ul> </td> <td>None reported</td> <td> <p>Infliximab (IV)</p> <p>Etanercept (SC)</p> <p>Certolizumab (SC)</p> <p>Golimumab (SC)</p> Adalimumab (SC)</td> <td> <p>Crohn disease</p> <p>Plaque psoriasis</p> <p>Psoriatic arthritis</p> <p>Rheumatoid arthritis</p> <p>Ulcerative colitis</p> <p>Ankylosing spondylitis</p> <p>Polyarticular juvenile idiopathic arthritis (pJIA)</p> <p>Hidradenitis suppurativa</p> Uveitis</td> </tr> <tr class="divider_bottom"> <td class="indent1">IFN-gamma</td> <td>T cells</td> <td> <ul> <li>Adhesion molecules, HLA-DR expression, activation of T cells, NK cells, macrophages</li> </ul> </td> <td>IFN-gamma 1b (SC): <ul class="decimal_heading"> <li>Chronic granulomatous disease (CGD)</li> <li>Malignant osteopetrosis</li> </ul> </td> <td>None reported</td> <td>None reported</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Colony-stimulating factors</td> </tr> <tr class="divider_bottom"> <td class="indent1">GM-CSF</td> <td> <p>Macrophages</p> <p>Fibroblasts</p> T cells</td> <td> <ul> <li>Myeloid differentiation, macrophage activation</li> </ul> </td> <td>Sargramostim (IV) <ul class="decimal_heading"> <li>Acute myeloid leukemia (AML)</li> <li>Bone marrow transplantation (BMT)</li> <li>Autologous peripheral blood stem cell mobilization and collection</li> <li>Hematopoietic radiation injury syndrome</li> </ul> </td> <td>None reported</td> <td>None reported</td> </tr> <tr class="divider_bottom"> <td class="indent1">G-CSF</td> <td>Macrophages</td> <td> <ul> <li>Granulocyte differentiation and activation</li> </ul> </td> <td>Filgrastim (SC), pegfilgrastim (SC), and tbo-filgrastim (SC): <ul class="decimal_heading"> <li>Myelosuppressive chemotherapy recipients with non-myeloid cancer</li> <li>Acute myeloid leukemia (AML)</li> <li>Bone marrow transplantation (BMT)</li> <li>Hematopoietic radiation injury syndrome</li> <li>Severe chronic neutropenia (SCN)</li> </ul> </td> <td>None reported</td> <td>None reported</td> </tr> <tr class="divider_bottom"> <td class="indent1">M-CSF</td> <td>Macrophages</td> <td> <ul> <li>Myeloid differentiation, macrophage activation</li> </ul> </td> <td>None reported</td> <td>None reported</td> <td>None reported</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Chemokines</td> </tr> <tr class="divider_bottom"> <td class="indent1">C-X-C family</td> <td>Many cells</td> <td> <ul> <li>Activate neutrophils, chemotactic to neutrophil (IL-8, ENA-78, etc) and T cells</li> </ul> </td> <td>None reported</td> <td>Anti-CXCR4 (SC)</td> <td>Peripheral stem cell mobilization</td> </tr> <tr class="divider_bottom"> <td class="indent1">C-C family</td> <td>Many cells</td> <td> <ul> <li>Chemotactic for monocytes and T cells (MCP-1, MIP-1, etc)</li> </ul> </td> <td>None reported</td> <td>None reported</td> <td>None reported</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Growth factors</td> </tr> <tr class="divider_bottom"> <td class="indent1">TGF-beta</td> <td>Many cells</td> <td> <ul> <li>Fibroblast proliferation, collagen and TIMP synthesis</li> <li>Decrease metalloproteinases, decreases T cell proliferation</li> <li>Angiogenesis, decreased proinflammatory cytokines</li> </ul> </td> <td> </td> <td>Pirfenidone (oral)</td> <td>Idiopathic pulmonary fibrosis</td> </tr> <tr class="divider_bottom"> <td class="indent1">FGF, VEGF</td> <td>Many cells</td> <td> <ul> <li>Fibroblast proliferation, angiogenesis</li> </ul> </td> <td> </td> <td>Anti-VEGF: <ul class="decimal_heading"> <li>Bevacizumab (IV)</li> <li>Ramucirumab (IV)</li> </ul> Anti-VEGF receptor: <ul class="decimal_heading"> <li>Ziv-aflibercept (IV)</li> </ul> Tyrosine kinase inhibitors to block VEGF: <ul class="decimal_heading"> <li>Cabozantinib (oral)</li> <li>Axitinib (oral)</li> <li>Vandetanib (oral)</li> </ul> Tyrosine kinase inhibitors to block VEGF and PDGF activity: <ul class="decimal_heading"> <li>Ponatinib (oral)</li> <li>Pazopanib (oral)</li> <li>Sunitinib (oral)</li> <li>Sorafenib (oral)</li> <li>Regorafenib (oral)</li> <li>Lenvatinib (oral)</li> </ul> </td> <td> <p>Cervical cancer</p> <p>Glioblastoma</p> <p>Ovarian, fallopian tube, or peritoneal cancer</p> <p>Soft-tissue sarcoma</p> <p>Renal cell carcinoma</p> <p>Medullary thyroid cancer</p> <p>Gastrointestinal stromal tumor</p> <p>Advanced pancreatic neuroendocrine tumor</p> <p>Hepatocellular carcinoma</p> <p>Colorectal cancer (metastatic)</p> <p>Acute lymphoblastic leukemia (ALL)</p> <p>Chronic myeloid leukemia (CML)</p> <p>Gastric cancer (advanced/metastatic)</p> Non-small cell lung cancer (NSCLC)</td> </tr> <tr> <td class="indent1">PDGF</td> <td>Many cells</td> <td> <ul> <li>Fibroblast proliferation</li> </ul> </td> <td> </td> <td>Anti-PDGF receptor alpha: <ul class="decimal_heading"> <li>Olaratumab</li> </ul> Tyrosine kinase inhibitors to block PDGF activity: <ul class="decimal_heading"> <li>Imatinib (oral)</li> <li>Dasatinib (oral)</li> <li>Nilotinib (oral)</li> <li>Bosutinib (oral)</li> </ul> Tyrosine kinase inhibitors to block VEGF and PDGF activity: <ul class="decimal_heading"> <li>Ponatinib (oral)</li> <li>Pazopanib (oral)</li> <li>Sunitinib (oral)</li> <li>Sorafenib (oral)</li> <li>Regorafenib (oral)</li> <li>Lenvatinib (oral)</li> </ul> </td> <td> <p>Soft-tissue sarcoma</p> <p>Acute lymphoblastic leukemia (ALL)</p> <p>Aggressive systemic mastocytosis</p> <p>Chronic myeloid leukemia (CML)</p> <p>Myelodysplastic syndrome</p> <p>Hypereosinophilic syndrome</p> <p>Gastrointestinal stromal tumor</p> Dermatofibrosarcoma protuberans</td> </tr> </tbody></table></div><div class="graphic_footnotes">IL: interleukin; FDA: Food and Drug Administration; SC: subcutaneous; OSP-101: Onspira 101; IV: intravenous; IgE: immunoglobulin E; Th1: T helper cell type 1; TIMP: tissue inhibitor of metalloproteinase; IFN: interferon; TNF: tumor necrosis factor; Th17: T helper cell type 17; HLA: human leukocyte antigen; NK: natural killer; GM-CSF: granulocyte-macrophage colony-stimulating factor; G-CSF: granulocyte colony-stimulating factor; M-CSF: macrophage colony-stimulating factor; C-X-C family: chemokines with two N-terminal cysteines (C) separated by one amino acid (X); ENA-78: epithelial cell-derived neutrophil-activating peptide; CXCR4: CXC chemokine receptor 4; C-C family: chemokines with two N-terminal cysteines (C); MCP-1: monocyte chemotactic protein 1; MIP-1: macrophage inflammatory protein 1; TGF: transforming growth factor; FGF: fibroblast growth factor; VEGF: vascular endothelial growth factor; PDGF: platelet-derived growth factor.</div><div id="graphicVersion">Graphic 69910 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
